TY - JOUR
AU1 - Voelker, Rebecca
AB - News & Analysis News From the Food and Drug Administration New Hereditary Angioedema Therapy Another Fluoroquinolone Approved toconductUSsurveillancestudiesfor5years A new medication for hereditary angio- The FDA has approved a new fluoroquino- to determine whether resistance to dela- lone antibiotic indicated for adults with edema (HAE), a rare disease that affects an floxacin develops in bacteria specified in the estimated 6000 to 10 000 people in the acute bacterial skin and skin structure infec- drug’s label. tions (ABSSSI) caused by specific gram- United States, has received FDA approval. Marketed as Haegarda, the drug is a C1 negative or gram-positive bacteria includ- Extended-Release ADHD Drug esterase inhibitor. People with HAE have in- ing methicillin-resistant Staphylococcus Another extended-release amphetamine- aureus and Pseudomonas aeruginosa. sufficient amounts or dysfunctional forms of dextroamphetamine combination medica- the plasma protein C1 esterase inhibitor, tion has received approval for the treat- which is part of the body’s complement sys- ment of attention-deficit/hyperactivity tem and plays a role in regulating inflamma- disorder (ADHD). Marketed as Mydayis, tion and coagulation. the drug is indicated for teens and adults. Without adequate amounts of the Children aged 12 years or younger should plasma protein, capillaries become leaky, not take the drug. which 
TI - New Hereditary Angioedema Therapy
JF - JAMA
DO - 10.1001/jama.2017.9334
DA - 2017-08-01
UR - https://www.deepdyve.com/lp/american-medical-association/new-hereditary-angioedema-therapy-CwzXSm9ymx
SP - 416
EP - 416
VL - 318
IS - 5
DP - DeepDyve
ER -